Amivantamab

Rybrevant

肺倍恩注射劑

350mg/7ml/vial

04. ANTINEOPLASTIC AGENTS; ;

04.06. PROTEIN- TYROSINE KINASE INHIBITORS;;

EGFR Inhibitor; MET Inhibitor

標靶藥物

X 動物或人體的試驗中或使用經驗發現對胎兒有害，而造成的傷害明顯大於可能的益處。

Unsafe

IVF
Non–small cell lung cancer, locally advanced or metastatic, with EGFR exon 19 deletion or exon 21 L858R substitution mutation, previously treated(in Combination with Pemetrexed and Carboplatin)
Week 1: 1,400 mg split over days 1 and 2 (350 mg on day 1(rate 50-75ml/hr) and 1,050 mg on day 2(rate 25 or 33-50ml/hr)).
Weeks 2 to 4: 1,400 mg once weekly.(rate 65-85-125ml/hr)
Weeks 5 and 6: No amivantamab dose.
Subsequent infusions (starting at week 7):(rate 125ml/hr)
Patients <80 kg: 1,750 mg once every 3 weeks.
Patients ≧80 kg: 2,100 mg once every 3 weeks.
Non–small cell lung cancer, locally advanced or metastatic, with EGFR exon 20 insertion mutation, first-line treatment(in Combination With Pemetrexed and Carboplatin)
Patients <80 kg:
Week 1: 1,400 mg split over days 1 and 2 (350 mg on day 1(rate 50-75ml/hr) and 1,050 mg on day 2(rate 33-50ml/hr)).
Weeks 2 to 4: 1,400 mg once weekly.(rate 65-85-125ml/hr)
Weeks 5 and 6: No amivantamab dose.
Subsequent infusions (starting at week 7): 1,750 mg once every 3 weeks.
Patients ≧80 kg:
Week 1: 1,750 mg split over days 1 and 2 (350 mg on day 1(rate 50-75ml/hr) and 1,400 mg on day 2(rate 25-50ml/hr)).
Weeks 2 to 4: 1,750 mg once weekly.(rate 65-85-125ml/hr)
Weeks 5 and 6: No amivantamab dose.
Subsequent infusions (starting at week 7): 2,100 mg once every 3 weeks.(rate 125ml/hr)
Non–small cell lung cancer, locally advanced or metastatic, with EGFR exon 20 insertion mutation, previously treated (single-agent therapy)
Patients <80 kg:
Week 1: 1,050 mg split over days 1 and 2 (350 mg on day 1 (rate 50-75ml/hr)and 700 mg on day 2(rate 33-50ml/hr)).
Weeks 2 to 5: 1,050 mg once weekly.(rate 65-85-125ml/hr)
Week 6: No amivantamab dose.
Subsequent infusions (starting at week 7): IV: 1,050 mg once every 2 weeks(rate 125ml/hr); continue until disease progression or unacceptable toxicity.
Patients ≧80 kg:
Week 1: 1,400 mg split over days 1 and 2 (350 mg on day 1(rate 50-75ml/hr) and 1,050 mg on day 2(rate 25-50ml/hr)).
Weeks 2 to 5: 1,400 mg once weekly.(rate 65-85-125ml/hr)
Week 6: No amivantamab dose.
Subsequent infusions (starting at week 7): 1,400 mg once every 2 weeks(rate 125ml/hr); continue until disease progression or unacceptable toxicity.

Skin rash, infusion related reaction, paronychia, musculoskeletal pain, dyspnea

1.藥品須冷藏於2-8℃
2.輸注時應使用具流量調節器及0.2mcg之過濾器輸注套組，勿與其他藥物通過同一靜脈注射管線。
3.治療期間及頭與最後一劑後3個月內，應採取有效避孕措施、不要哺乳。
4.治療期間應限制陽光直射、使用廣效性UVA/UVB防曬乳並穿著防曬衣物，並建議使用不含酒精成分乳液。
5.藥品備製：
(1)先自250ml 0.9%NaCl或5% Dextrose輸注液中，抽取與準備加入之Rybrevant體積相等之溶液量，予以丟棄(加入3vial Rybrevant就需從輸注液中抽取21ml丟棄)。
(2)將所需Rybrevant加入輸注液袋中(限使用PVC、PE、PP+PE材質)
(3)輕輕翻轉輸注袋，使溶液混合均勻。
(4)於20-25℃室溫下，稀釋後溶液應於10小時內輸注完畢。

建立者

103617

建立時間

2023-12-27 15:19:20

維護者

103617

維護時間

2026-01-07 14:18:49